Inventor · disambiguated record
Robert Huerta Lemus
Also filed as: LEMUS ROBERT · LEMUS ROBERT H · LEMUS ROBERT HUERTA
24 granted patents·14 pending applications·73 citations·filing 1991–2025
95Inventor score
Files withOMEROS CORP14DART NEUROSCIENCE CAYMAN LTD9METABASIS THERAPEUTICS INC7DART NEUROSCIENCE LLC5GOMEZ-GALENO JORGE E2
Top patents by PatentIndex Score
38 records- 0192US11661418B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2020·Granted May 30, 2023·4 cites·21 claims
- 0290US11807641B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2020·Granted Nov 7, 2023·2 cites·18 claims
- 0389US12195427B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2022·Granted Jan 14, 2025·1 cites·18 claims
- 0488US9932345B2Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2015·Granted Apr 3, 2018·3 cites·35 claims
- 0587US11584714B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2019·Granted Feb 21, 2023·5 cites·13 claims
- 0687US8710236B2Antagonists of the glucagon receptorGOMEZ-GALENO JORGE E·Filed 2011·Granted Apr 29, 2014·10 cites·5 claims
- 0787US2025122172A1Substituted pyridine and pyrazine compounds as pde4 inhibitorsDART NEUROSCIENCE LLC·Filed 2024·Application pending·0 cites
- 0886US9701626B2Antagonists of the glucagon receptorMETABASIS THERAPEUTICS INC·Filed 2015·Granted Jul 11, 2017·5 cites·10 claims
- 0986US9169201B2Antagonists of the glucagon receptorMETABASIS THERAPEUTICS INC·Filed 2014·Granted Oct 27, 2015·8 cites·13 claims
- 1086US8907103B2Glucagon antagonistsGOMEZ-GALENO JORGE E·Filed 2009·Granted Dec 9, 2014·10 cites·19 claims
- 1185US2025092047A1Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitorsDART NEUROSCIENCE LLC·Filed 2024·Application pending·0 cites
- 1283US2025129020A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2024·Application pending·0 cites
- 1383US2025011323A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2024·Application pending·0 cites
- 1481US9120770B2Substituted pyridine and pyrazine compounds as PDE4 inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2014·Granted Sep 1, 2015·3 cites·30 claims
- 1580US10239829B2Antagonists of the glucagon receptorMETABASIS THERAPEUTICS INC·Filed 2017·Granted Mar 26, 2019·2 cites·20 claims
- 1679US10239882B2Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2015·Granted Mar 26, 2019·2 cites·20 claims
- 1779US9783494B2Glucagon antagonistsMETABASIS THERAPEUTICS INC·Filed 2014·Granted Oct 10, 2017·3 cites·21 claims
- 1879US2023075774A1Substituted pyridine and pyrazine compounds as pde4 inhibitorsDART NEUROSCIENCE LLC·Filed 2022·Application pending·0 cites
- 1978US11186582B2Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2019·Granted Nov 30, 2021·0 cites·20 claims
- 2078US9040692B2Substituted pyridine and pyrazine compounds as PDE4 inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2014·Granted May 26, 2015·2 cites·1 claims
- 2177US2023192698A1Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitorsDART NEUROSCIENCE LLC·Filed 2022·Application pending·0 cites
- 2275US12486278B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2023·Granted Dec 2, 2025·0 cites·19 claims
- 2375US10221130B2Glucagon antagonistsMETABASIS THERAPEUTICS INC·Filed 2017·Granted Mar 5, 2019·1 cites·14 claims
- 2475US2025243198A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2025·Application pending·0 cites
- 2574US9573937B2Substituted pyridine and pyrazine compounds as PDE4 inhibitorsDART NEUROSCIENCE (CAYMAN) LTD·Filed 2015·Granted Feb 21, 2017·1 cites·20 claims
- 2674US2025376443A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2025·Application pending·0 cites
- 2773US11352321B2Glucagon antagonistsMETABASIS THERAPEUTICS INC·Filed 2019·Granted Jun 7, 2022·0 cites·15 claims
- 2873US11279691B2Substituted pyridine and pyrazine compounds as PDE4 inhibitorsDART NEUROSCIENCE LLC·Filed 2019·Granted Mar 22, 2022·0 cites·4 claims
- 2971US2025368604A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2025·Application pending·0 cites
- 3069US12110288B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2020·Granted Oct 8, 2024·0 cites·17 claims
- 3168US10807946B2Antagonists of the glucagon receptorMETABASIS THERAPEUTICS INC·Filed 2019·Granted Oct 20, 2020·0 cites·10 claims
- 3267US2025066383A1Pde 7 modulator compoundsOMEROS CORP·Filed 2024·Application pending·0 cites
- 3365US2018346448A1Substituted pyridine and pyrazine compounds as pde4 inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2018·Application pending·0 cites
- 3465US2025122225A1Masp-2 inhibitors and methods of useOMEROS CORP·Filed 2024·Application pending·0 cites
- 3564US2016009691A1Substituted pyridine and pyrazine compounds as pde4 inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2014·Application pending·0 cites
- 3661US10501465B2Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitorsDART NEUROSCIENCE CAYMAN LTD·Filed 2018·Granted Dec 10, 2019·0 cites·22 claims
- 3757US2023285556A1Methods and compositions for treating cancerOMEROS CORP·Filed 2022·Application pending·0 cites
- 3855US5639881ASynthesis and elucidation of pyrimido (4,5-Q) quinazoline derivativesUNIV ARIZONA·Filed 1991·Granted Jun 17, 1997·11 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when Robert Huerta Lemus files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →